Bone graft alternatives in spinal fusion surgery

Current Opinion in Orthopaedics

Volumn 14, Issue 3, 2003, Pages 127-137

  Kim, David H ^a   Jenis, Louis ^a   Berta, Scott C ^b   Vaccaro, Alexander R ^b  

^a Boston Spine Group   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; OSTEOGENIC PROTEIN 1;

ALLOGRAFT; AUTOGRAFT; BONE CONDUCTION; BONE DEVELOPMENT; BONE GRAFT; BONE MARROW BIOPSY; BONE MATRIX; CERAMICS; CLINICAL TRIAL; COMPOSITE GRAFT; DEMINERALIZATION; HUMAN; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINE FUSION; SPINE SURGERY; STEM CELL;

EID: 0037530142     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-200306000-00002     Document Type: Review

References (73)

1. Boden SD, Schimandle JH, Hutton WC: 1995 Volvo award in basic sciences: the use of an osteoinductive growth factor for lumbar spinal fusion. Part II: study of dose, carrier, and species. Spine 1995, 20:2633-2644.
2. Muschler GF, Boehm C, Easley K: Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg 1997, 79:1699-1709.
3. Dodd CAF, Fergusson CM, Freedman L, et al.: Allograft versus autograft bone in scoliosis surgery. J Bone Joint Surg Br 1988, 70:431-434.
4. Ehrler DM, Vaccaro AR: The use of allograft bone in lumbar spine surgery. Clin Orthop 2000, 371:38-45.
5. Ludwig SC, Boden SD: Osteoinductive bone graft substitutes for spinal fusion: a basic science summary. Orthop Clin North Am 1999, 30:635-645.
6. Finkemeier CG: Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 2002, 84A:454-464.
7. Fleming JEJ, Cornell CN, Muschler GF: Bone cells and matrices in orthopedic tissue engineering. Orthop Clin North Am 2000, 31:357-374.
8. Aspenberg P, Johnsson E, Thorngren KG: Dose-dependent reduction of bone inductive properties by ethylene oxide. J Bone Joint Surg Br 1990, 72:1036-1037.
9. Munting E, Wilmart JF, Wijne A, et al.: Effect of sterilization on osteoinduction: comparison of five methods in demineralized rat bone. Acta Orthop Scand 1988, 59:34-38.
10. Bauer TW, Smith ST: Bioactive materials in orthopaedic surgery: overview and regulatory considerations. Clin Orthop Rel Res 2002, 395:11-22.
11. Groeneveld EHJ, Burger EH: Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol 2000, 142:9-21.
12. Sassard WR, Eidman DK, Gray PMJ, et al.: Augmenting local bone with Grafton demineralized bone matrix for posterolateral lumbar spine fusion: avoiding second site autologous bone harvest. Orthopedics 2000, 23:1059-1065.
13. Greenwald AS, Boden SD, Goldberg VM, et al.: Bone-graft substitutes: facts, fictions, and applications. J Bone Joint Surg Am 2001, 83A:98-103.
14. Gazdag AR, Lane JM, Glaser DL, et al.: Alternatives to autogenous bone graft: efficacy and indications. J Am Acad Orthop Surg 1995, 3:1-8.
15. Petruskevicius J, Nielsen S, Kaalund S, et al.: No effect of OsteoSet, a bone graft substitute, on bone healing in humans. Acta Orthop Scand 2002, 73:575-578.
16. Yamamoto T, Onga T, Marui T, et al.: Use of hydroxyapatite to fill cavities after excision of benign bone tumors. J Bone Joint Surg Br 2000, 82B:1117-1120.
17. Betz RR: Limitations of autograft and allograft: new synthetic solutions. Orthopedics 2002, 25:S561-S570.
18. Erbe E: Chemistry and resorption characteristics of a synthetic cancellous bone void filler, an ultraporous beta-tricalcium phosphate scaffold. Presented at the World Spine I: First Interdisciplinary World Congress on Spinal Surgery. Berlin, Germany. August 28-September 1, 2000.
19. Hollinger JO, Brekke J, Gruskin E, et al.: Role of bone substitutes. Clin Orthop 1996, 324:55-65.
20. Meadows G, Crimmins S, LeCea J: Adjunctive use of ultraporous beta-TCP bone void filler in spinal arthrodesis. Orthopedics 2002, in press.
21. Ohyama T, Kubo Y, Iwata H, et al.: Beta-tricalcium phosphate as a substitute for autograft in interbody fusion cages in the canine lumbar spine. J Neurosurg 2002, 97:350-354.
22. Ransford AO, Morley T, Edgar MA, et al.: Synthetic porous ceramic compared with autograft in scoliosis surgery: a prospective, randomized study of 341 patients. J Bone Joint Surg Br 1998, 80:13-18. Published erratum appears in J Bone Joint Surg Br 1998, 80:562.
23. Cavagna R, Daculsi G, Bouler JM: Macroporous calcium phosphate ceramic: a prospective study of 106 cases in lumbar spinal fusion. J Long Term Eff Med Implants 1999, 9:403-412.
24. Constantz BR, Ison IC, Fulmer MT, et al.: Skeletal repair by in situ formation of the mineral phase of bone. Science 1995, 267:1796-1799.
25. Cornell CN: Osteoconductive materials and their role as substitutes for autogenous bone grafts. Orthop Clin North Am 1999, 30:591-598.
26. Muschler GF, Negami S, Hyodo A, et al.: Evaluation of collagen ceramic composite graft materials in a spinal fusion model. Clin Orthop 1996, 328:250-260.
27. Zerwekh JE, Kourosh S, Schienberg R, et al.: Fibrillar collagen-biphasic calcium phosphate composite as a bone graft substitute for spinal fusion. J Orthop Res 1992, 10:562-572.
28. Walsh WR, Harrison J, Loefler A, et al.: Mechanical and histologic evaluation of Collagraft in an ovine lumbar fusion model. Clin Orthop 2000, 375:258-266.
29. Cornell CN, Lane JM, Chapman M, et al.: Multicenter trial of collagraft as bone graft substitute. J Orthop Trauma 1991, 5:1-8.
30. Papavero L, Zwonitzer R, Burkard I, et al.: A composite bone graft substitute for anterior cervical fusion. Spine 2002, 27:1037-1043.
31. Urist MR: Practical application of basic research on bone graft physiology. Instructional Course Lectures 1976, 25:1-26.
32. Wozney JM: Bone morphogenetic proteins. Prog Growth Factor Res 1989, 1:267-280.
33. Kim KH, Itoh T, Kotake S: Effects of recombinant human bone morphogenetic protein-2 on human bone marrow cells cultured with various biomaterials. J Biomed Mater Res 1997, 35:279-285.
34. Mayer H, Scutt AM, Ankenbauer T: Subtle differences in the mitogenic effects of recombinant human bone morphogenetic proteins-2 to -7 on DNA synthesis in primary bone-forming cells and identification of BMP-2/4 receptor. Calcif Tissue Int 1996, 58:249-255.
35. Boden SD, McCuaig K, Hair G, et al.: Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. Endocrinology 1996, 137:3401-3407.
36. Hughes FJ, Collyer J, Stanfield M, et al.: The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 1995, 136:2671-2677.
37. Cheline AJ, Reddi AH, Martin RB: Bone morphogenetic protein-7 selectively enhances mechanically induced bone formation. Bone 2002, 31:570-574.
38. Graff JM, Bansal A, Melton DA: Xenopus MAD proteins transduce distinct subsets of signals for the TGF beta superfamily. Cell 1996, 85:479-487.
39. Boden SD: Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng 2000, 6:383-399.
40. Postlethwaite AE, Raghow R, Stricklin G, et al.: Osteogenic protein-1, a bone morphogenic protein member of the TGF-beta superfamily, shares chemotactic but not fibrogenic properties with TGF-beta. J Cell Physiol 1994, 161:562-570.
41. Boyan BD, Schwartz Z, Swain LD, et al.: Initial effects of partially purified bone morphogenetic protein on the expression of glycosaminoglycan, collagen, and alkaline phosphatase in nonunion cell cultures. Clin Orthop Rel Res 1992, 278:286-304.
42. Yasko AW, Lane JM, Fellinger FJ, et al.: The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2): a radiographic, histologic, and biomechanical study in rats. J Bone Joint Surg Am 1992, 74:659-670.
43. Urist MR, Sato K, Brownell AG, et al.: Human bone morphogenetic protein (hBMP). Proc Soc Exp Biol Med 1983, 173:194-199.
44. Ripamonti U, Van Den Heever B, Sampath TK, et al.: Complete regeneration of bone in the baboon by recombinant human osteogenic protein-1 (hOP-1, bone morphogenetic protein-7). Growth Factors 1996, 13:273-289.
45. Sciadini MF, Johnson KD: Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 2000, 18:289-302.
46. Boyne PJ: Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 2001, 83A:S1-146-S1-150.
47. Schimandle JH, Boden SD, Hutton WC: Experimental spinal fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2). Spine 1995, 20:1326-1337.
48. Martin GJ, Boden SD, Morone MA, et al.: Posterolateral intertransverse process spinal fusion arthrodesis with rhBMP-2 in a non-human primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999, 12:179-186.
49. Boden SD, Martin GJ, Morone MA, et al.: Posterolateral lumbar intertransverse process spine arthrodesis with rhBMP-2/hydroxyapatite-tricalcium phosphate (HA-TCP) following laminectomy in the non-human primate. Spine 1999, 24:1179-1185.
50. Boden SD, Moskovitz PA, Monroe MA, et al.: Video-assisted lateral intertransverse process arthrodesis: validation of a new minimally invasive lumbar spinal fusion technique in the rabbit and nonhuman primate (rhesus) models. Spine 1996, 21:2689-2697.
51. Boden SD, Martin GJ, Horton WC, et al.: Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J Spinal Disord 1998, 11:95-101.
52. Boden SD, Zdeblick TA, Sandhu HS, et al.: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000, 25:376-381.
53. Sandhu HS, Grewal HS, Parvataneni H: Bone grafting for spinal fusion. Orthop Clin North Am 1999, 30:685-698.
54. Boden SD, Kang J, Sandhu HS, et al.: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans. Spine 2002, 27:2662-2673.
55. Burstein FD: Bone substitutes. Cleft Palate Craniofacial J 2000, 37:1-4.
56. Miki T, Masaka K, Imai Y, et al.: Experience with freeze-dried PGLA/HA/rhBMP-2 as a bone graft substitute. J Craniomaxillofac Surg 2000, 28:294-299.
57. Toth JM, Estes BT, Wang M, et al.: Evaluation of 70/30 poly (L-lactide-co-D,L-lactide) for use as a resorbable interbody fusion cage. J Neurosurg 2002, 97:423-432.
58. Cunningham BW, Shimamoto N, Sefter JC, et al.: Posterolateral spinal arthrodesis using osteogenic protein-1: an in-vivo time course study using a canine model. Presented at the 15th annual meeting of the North American Spine Society. New Orleans, LA. October 25-28, 2000.
59. Patel TC, Erulkar JS, Grauer JN, et al.: OP-1 overcomes the inhibitory effect of nicotine on posterolateral lumbar fusion. Presented at the 15th annual meeting of the North American Spine Society. New Orleans, LA. October 25-28, 2000.
60. Magin MN, Delling G: Improved lumbar vertebral interbody fusion using rhOP-1: a comparison of autogenous bone graft, bovine hydroxyapatite (BioOss), and BMP-7 (rhOP-1) in sheep. Spine 2001, 26:469-478.
61. Patel TC, Vaccaro AR, Truumees E, et al.: A safety and efficacy study of OP-1 (rhBMP-7) as an adjunct to posterolateral lumbar fusion. Presented at the 15th annual meeting of the North American Spine Society. New Orleans, LA. October 25-28, 2000.
62. Patel TC, Hopkinton MA, Vaccaro AR, et al.: Two-year follow up of a safety and efficacy study of OP-1 (rhBMP-7) as an adjunct to posterolateral lumbar fusion. Presented at the 16th annual meeting of the North American Spine Society. Seattle, WA. 2001.
63. Fischgrund JS, Mackay M, Herkowitz HN, et al.: 1997 Volvo award winner in clinical studies. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine 1997, 22:2807-2812.
64. Johnsson R, Stromqvist B, Aspenberg P: Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion. Spine 2002, 27:2654-2661.
65. Boden SD, Schimandle JH, Hutton WC: Lumbar intertransverse process spinal arthrodesis with use of a bovine bone-derived osteoinductive protein. J Bone Joint Surg Am 1995, 77:1404-1417.
66. Boden SD, Schimandle JH, Hutton WC: The use of an osteoinductive growth factor for lumbar spinal fusion: part II. Study of dose, carrier, and species. Spine 1995, 20:2633-2644.
67. Damien CJ, Grob D, Boden SD, et al.: Purified bovine BMP extract and collagen for spine arthrodesis. Spine 2002, 27:S50-S58.
68. Aghaloo TL, Moy PK, Freymiller EG: Investigation of platelet-rich plasma in rabbit cranial defects: a pilot study. J Oral Maxillofac Surg 2002, 60:1176-1181.
69. Marx RE, Carlson ER, Eichstaedt RM, et al.: Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol 1998, 85:638.
70. Tischler M: Platelet rich plasma: the use of autologous growth factors to enhance bone and soft tissue grafts. N Y State Dent J 2002, 68:22-24.
71. Camargo PM, Lekovic V, Weinlaender M, et al.: Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. J Periodont Res 2002, 37:300-306.
72. Sonnleitner D, Huemer P, Sullivan DY: A simplified technique for producing platelet-rich plasma and platelet concentrate for intraoral bone grafting techniques: a technical note. Int J Oral Maxillofac Implants 2000, 15:879-892.
73. McAlinden MG, Wilson DJ: Comparison of cancellous bone-derived cell proliferation in autologous human and fetal bovine serum. Cell Transplant 2000, 9:445-451.